Oramed Pharmaceuticals Inc.
ORMP
$2.73
-$0.02-0.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 882.13% | -215.82% | -370.07% | -444.98% | 127.30% |
| Total Depreciation and Amortization | -43.26% | -34.10% | -22.33% | -1.53% | 34.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -290.97% | 141.24% | 206.79% | 154.47% | -602.52% |
| Change in Net Operating Assets | 96.85% | -187.92% | 189.86% | 218.69% | 172.00% |
| Cash from Operations | -33.73% | -962.57% | -68.03% | 18.29% | 53.25% |
| Capital Expenditure | -80.00% | 37.84% | 66.67% | 92.91% | 98.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -81.25% | -162.90% | 433.96% | 245.41% | 231.96% |
| Cash from Investing | -81.27% | -162.96% | 433.26% | 244.88% | 231.18% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | 100.00% | 100.00% | 55.72% | 0.90% | -198.20% |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -49.26% | -142,750.00% | -124,200.00% | -124,200.00% | -64,450.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 97.46% | -142,750.00% | -208.14% | -200.11% | -193.45% |
| Foreign Exchange rate Adjustments | 583.33% | 242.86% | 76.47% | 92.59% | 103.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.50% | -188.42% | 1,111.94% | 244.43% | 232.13% |